Similar articles

• The role of percutaneous revascularization in the treatment of ischemic heart disease: insights from published reports and randomized clinical trials.

  Levine GN, Ali MN. Levine GN, et al. Chest. 1997 Sep;112(3):805-21. doi: 10.1378/chest.112.3.805. Chest. 1997. PMID: 9315818 Review. No abstract available.
• [Percutaneous coronary revascularization today: considerations on the use of stents].

  Orrego PS, Klugmann S. Orrego PS, et al. G Ital Cardiol. 1999 Oct;29(10):1246-58. G Ital Cardiol. 1999. PMID: 10546143 Review. Italian. No abstract available.
• Putting the benefits of percutaneous coronary revascularization into perspective: from trials to guidelines.

  Sharma K, Eisenberg MJ. Sharma K, et al. Curr Cardiol Rep. 2008 Sep;10(5):393-401. doi: 10.1007/s11886-008-0062-9. Curr Cardiol Rep. 2008. PMID: 18715536 Review.
• [Impact of GP IIb/IIIa antagonists in interventional cardiology].

  Scheller B, Hennen B, Böhm M, Nickenig G. Scheller B, et al. Dtsch Med Wochenschr. 2003 Feb 7;128(6):281-7. doi: 10.1055/s-2003-37078. Dtsch Med Wochenschr. 2003. PMID: 12571800 Review. German. No abstract available.
• [Acute coronary syndromes without ST-elevation -- treatment].

  Weber M, Hamm C. Weber M, et al. Dtsch Med Wochenschr. 2003 Feb 7;128(6):273-6. doi: 10.1055/s-2003-37072. Dtsch Med Wochenschr. 2003. PMID: 12571797 German. No abstract available.